Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Treasury Shares (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Treasury Shares for 7 consecutive years, with $2.5 million as the latest value for Q4 2025.

  • Quarterly Treasury Shares fell 1.28% to $2.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.5 million through Dec 2025, down 1.28% year-over-year, with the annual reading at $2.5 million for FY2025, 1.28% down from the prior year.
  • Treasury Shares for Q4 2025 was $2.5 million at Beam Therapeutics, down from $2.8 million in the prior quarter.
  • The five-year high for Treasury Shares was $3.4 million in Q1 2024, with the low at $1.1 million in Q4 2021.
  • Average Treasury Shares over 5 years is $2.2 million, with a median of $2.2 million recorded in 2023.
  • The sharpest move saw Treasury Shares tumbled 38.79% in 2021, then skyrocketed 72.92% in 2023.
  • Over 5 years, Treasury Shares stood at $1.1 million in 2021, then skyrocketed by 50.31% to $1.7 million in 2022, then surged by 72.92% to $2.9 million in 2023, then dropped by 11.97% to $2.6 million in 2024, then fell by 1.28% to $2.5 million in 2025.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $2.5 million, $2.8 million, and $2.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.